Advances in the Use of Targeted Therapies in the Management of Non–Small Cell Lung Cancer

摘要

Mutation-targeted therapies have had a major impact on the treatment of NSCLC, even for patients with advanced disease. Methods for detecting mutations, key clinical trials of targeted therapy, and the most common toxicities of EGFR and ALK inhibition were discussed at JADPRO Live.